Annexon Touts Final Huntington’s Trial Data Confirming No New Safety Issues
Annexon Inc (NASDAQ: ANNX)
Annexon Biosciences Reports Phase 2 Clinical Trial Results Showing ANX005 Demonstrated Full C1q Target Inhibition And Was Generally Well-Tolerated
ANX005 Demonstrated Full C1q Target Inhibition and Was Generally Well-Tolerated
Disease Progression Stabilized in Overall Patient Population Through the Nine-month Study
Rapid Improvement in Clinical Outcome
10 Biggest Price Target Changes For Tuesday
Keybanc cut PubMatic, Inc. (NASDAQ: PUBM) price target from $48 to $27. PubMatic shares fell 1.5% to $18.71 in pre-market trading.
53 Biggest Movers From Yesterday
Gainers
ION Geophysical Corporation (NYSE: IO) shares surged 91.2% to settle at $0.6980 on Wednesday. ION Geophysical was awarded a five-year contract by Brunei Shell Petroleum Co. for a digital solution to manage Marine Logistics.
23 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
ToughBuilt Industries, Inc. (NASDAQ: TBLT) rose 44.9% to $0.2125 in pre-market trading as the company posted a narrower FY21 loss.
Stocks That Hit 52-Week Lows On Friday
During Friday's morning session, 234 stocks hit new 52-week lows.
Needham Maintains Buy on Annexon, Lowers Price Target to $24
Needham analyst Joseph Stringer maintains Annexon (NASDAQ:ANNX) with a Buy and lowers the price target from $37 to $24.